Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety Extension of rFXIII in Pediatric Congenital Factor XIII Deficiency
NCT01253811Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2011
- Primary completion
- Mar 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 3
01
Overview
Phase 3, open-label, single-arm trial of catridecacog, sponsored by Novo Nordisk. Primary endpoint: Number of Treatment Emergent (Serious and Non-serious) Adverse Events. Started Jan 2011; status: completed.
02
Drugs
catridecacog
Beyond the preview
Go deeper on NCT01253811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01253811.